Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative / myelodysplastic disorders : an analysis of 636 cases
暂无分享,去创建一个
A. Kohlmann | T. Haferlach | S. Schnittger | W. Kern | C. Haferlach | A. Reiter | A. Kowarsch | V. Grossmann | T. Alpermann | U. Bacher | F. Dicker | M. Ulke | C. Eder
[1] M. García-Delgado,et al. CBL mutations in myeloproliferative neoplasms are also found in the gene’s proline-rich domain and in patients with the V617FJAK2 , 2012, Haematologica.
[2] A. Kohlmann,et al. ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome , 2011 .
[3] Michael A McDevitt,et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. , 2011, Blood.
[4] A. Kohlmann,et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases , 2011, Leukemia.
[5] A. Kohlmann,et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance , 2011, Leukemia.
[6] Martin Dugas,et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Kusec,et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. , 2010, Blood.
[8] A. Kohlmann,et al. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis , 2010, Haematologica.
[9] M. Loh,et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. , 2009, Blood.
[10] S. Ogawa,et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms , 2009, Nature.
[11] W. Hiddemann,et al. CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes , 2009, Clinical Cancer Research.
[12] T. Haferlach,et al. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera , 2009, Haematologica.
[13] M. McDevitt,et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. , 2008, Cancer research.
[14] A. Hall,et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. , 2008, Blood.
[15] T. Haferlach,et al. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis , 2008, Leukemia.
[16] T. Haferlach,et al. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. , 2007, Blood.
[17] T. Haferlach,et al. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E , 2006, Leukemia.
[18] T. Seriu,et al. Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology , 2000, Leukemia.
[19] R. Arceci. Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies , 2010 .
[20] Professor Dr. med. Helmut Löffler,et al. Atlas of Clinical Hematology , 2000, Springer Berlin Heidelberg.
[21] J. Melo,et al. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. , 1994, Leukemia.